New tuberculosis drug leads from naturally occurring compounds

被引:76
作者
Quan, Diana [1 ,2 ]
Nagalingam, Gayathri [1 ,2 ]
Payne, Richard [3 ]
Triccas, James A. [1 ,2 ,4 ]
机构
[1] Univ Sydney, Sydney Med Sch, Dept Infect Dis & Immunol, Microbial Pathogenesis & Immun Grp, Sydney, NSW, Australia
[2] Univ Sydney, Centenary Inst, TB Res Program, Sydney, NSW, Australia
[3] Univ Sydney, Sch Chem, Sydney, NSW, Australia
[4] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
tuberculosis; natural product; drug development; clinical trial; MULTIDRUG-RESISTANT TUBERCULOSIS; KILLS MYCOBACTERIUM-TUBERCULOSIS; ACID CONDENSING ENZYME; GRAMINIS VAR TRITICI; IN-VITRO; PULMONARY TUBERCULOSIS; BACTERICIDAL ACTIVITY; ANTIMYCOBACTERIAL ACTIVITIES; PSEUDOMONAS-FLUORESCENS; ANTIBACTERIAL ACTIVITY;
D O I
10.1016/j.ijid.2016.12.024
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Tuberculosis (TB) continues to be a significant cause of mortality and morbidity worldwide. An estimated 2 billion individuals are infected with Mycobacterium tuberculosis and annually there are approximately 10 million new cases of clinical TB and 1.5 million deaths. Currently available drugs and vaccines have had no significant impact on TB control. In addition, the emergence of drug resistant TB is considered a public health crisis, with some strains now resistant to all available drugs. Unfortunately, the growing burden of antibiotic resistance is coupled with decreased effort in the development of new antibiotics. Natural sources are attractive starting points in the search for anti- tubercular drugs because they are extremely rich in chemical diversity and have privileged antimicrobial activity. This review will discuss recent advances in the development of TB drug leads from natural products, with a particular focus on antimycobacterial compounds in late- stage preclinical and clinical development. (C) 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
引用
收藏
页码:212 / 220
页数:9
相关论文
共 118 条
  • [1] Natural antimicrobial peptides against Mycobacterium tuberculosis
    Abedinzadeh, Maria
    Gaeini, Mahdieh
    Sardari, Soroush
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (05) : 1285 - 1289
  • [2] Antimicrobial peptides (AMPs): Ancient compounds that represent novel weapons in the fight against bacteria
    Ageitos, J. M.
    Sanchez-Perez, A.
    Calo-Mata, P.
    Villa, T. G.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2017, 133 : 117 - 138
  • [3] Activity of the Fluoroquinolone DC-159a in the Initial and Continuation Phases of Treatment of Murine Tuberculosis
    Ahmad, Zahoor
    Minkowski, Austin
    Peloquin, Charles A.
    Williams, Kathy N.
    Mdluli, Khisimuzi E.
    Grosset, Jacques H.
    Nuermberger, Eric L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (04) : 1781 - 1783
  • [4] Emerging Trends in Genomic Approaches for Microbial Bioprospecting
    Akondi, K. B.
    Lakshmi, V. V.
    [J]. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2013, 17 (02) : 61 - 70
  • [5] Anderson T., 1850, LIEBIGS ANN CHEM, V75, P80
  • [6] A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis
    Andries, K
    Verhasselt, P
    Guillemont, J
    Göhlmann, HWH
    Neefs, JM
    Winkler, H
    Van Gestel, J
    Timmerman, P
    Zhu, M
    Lee, E
    Williams, P
    de Chaffoy, D
    Huitric, E
    Hoffner, S
    Cambau, E
    Truffot-Pernot, C
    Lounis, N
    Jarlier, V
    [J]. SCIENCE, 2005, 307 (5707) : 223 - 227
  • [7] Arnone AN, 2016, J CHEM SOC PERK T, V1, P1353
  • [8] Total Synthesis of Cyclomarin A, a Marine Cycloheptapeptide with Anti-Tuberculosis and Anti-Malaria Activity
    Barbie, Philipp
    Kazmaier, Uli
    [J]. ORGANIC LETTERS, 2016, 18 (02) : 204 - 207
  • [9] Bedeschi A, 2016, NAT PROD COMMUN, V11, P569
  • [10] Origins of the Quinolone Class of Antibacterials: An Expanded "Discovery Story"
    Bisacchi, Gregory S.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (12) : 4874 - 4882